Akio Kuroda1, Miho Tsuruo2, Nanako Aki3, Takeshi Kondo4, Yukari Oguro5, Motoyuki Tamaki1, Ken-Ichi Aihara4, Itsuro Endo4, Toshio Matsumoto4,6, Masahiro Abe4, Munehide Matsuhisa1. 1. 1Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15, Kuramoto-cho, Tokushima, 770-8503 Japan. 2. Terasawa Hospital, Tokushima, Japan. 3. Department of Internal Medicine, Anan Kyoei Hospital, Anan, Japan. 4. 4Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. 5. Department of Internal Medicine, Takamatsu Municipal Hospital, Kagawa, Japan. 6. 6Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, Japan.
Abstract
AIMS: To compare the diurnal glycemic profiles obtained with basal insulin degludec (InsDeg) and basal insulin glargine (InsGla) in patients with type 1 diabetes using continuous glucose monitoring (CGM) in an outpatient setting. METHODS: Twenty Japanese patients with type 1 diabetes who were using once-daily InsGla before supper as part of their multiple daily insulin injections were consecutively recruited. CGM was initiated before supper on day 1, and InsGla was switched to InsDeg at the same dose on day 3. The average CGM glucose profile obtained on days 1 and 2 was compared with the corresponding profile for days 5 and 6. The bolus insulin regimen was not changed during the study period. RESULTS: CGM glucose was significantly higher (p < 0.05) from 19:30 to 22:30 and significantly lower (p < 0.05) from 6:30 to 8:00 with basal InsDeg than with basal InsGla. The duration of hypoglycemia (<70 mg/dl) was the same regardless of whether basal InsDeg or basal InsGla was used. CONCLUSIONS: The peak in the action profile of InsDeg lasts longer and is possibly stronger than that of InsGla.
AIMS: To compare the diurnal glycemic profiles obtained with basal insulin degludec (InsDeg) and basal insulin glargine (InsGla) in patients with type 1 diabetes using continuous glucose monitoring (CGM) in an outpatient setting. METHODS: Twenty Japanese patients with type 1 diabetes who were using once-daily InsGla before supper as part of their multiple daily insulin injections were consecutively recruited. CGM was initiated before supper on day 1, and InsGla was switched to InsDeg at the same dose on day 3. The average CGM glucose profile obtained on days 1 and 2 was compared with the corresponding profile for days 5 and 6. The bolus insulin regimen was not changed during the study period. RESULTS: CGM glucose was significantly higher (p < 0.05) from 19:30 to 22:30 and significantly lower (p < 0.05) from 6:30 to 8:00 with basal InsDeg than with basal InsGla. The duration of hypoglycemia (<70 mg/dl) was the same regardless of whether basal InsDeg or basal InsGla was used. CONCLUSIONS: The peak in the action profile of InsDeg lasts longer and is possibly stronger than that of InsGla.
Authors: Simon Heller; John Buse; Miles Fisher; Satish Garg; Michel Marre; Ludwig Merker; Eric Renard; David Russell-Jones; Areti Philotheou; Ann Marie Ocampo Francisco; Huiling Pei; Bruce Bode Journal: Lancet Date: 2012-04-21 Impact factor: 79.321
Authors: Francesca Porcellati; Paolo Rossetti; Natalia Ricci Busciantella; Stefania Marzotti; Paola Lucidi; Steven Luzio; David R Owens; Geremia B Bolli; Carmine G Fanelli Journal: Diabetes Care Date: 2007-07-10 Impact factor: 19.112